Kupferschmidt R, Schmid R W
Laboratory of Psychoactive Drug Analysis, Psychiatric University Hospital, Vienna, Austria.
Clin Chem. 1989 Jul;35(7):1313-7.
A simple isocratic HPLC method for determining azidothymidine (AZT) in serum and plasma of patients has been developed. The novel, specific, two-step, solid-phase extraction approach used for sample preparation gives a nearly quantitative recovery (95.3%) of AZT from the blood plasma matrix and requires only minimal handling of infectious clinical samples. Automatic "on-line" injection is achieved with an AASP system by switching a small cartridge, which retains the extracted analyte, into the HPLC stream. The overall HPLC procedure shows satisfying reproducibility with low standard deviation (CV: 2.1%). Because of the low detection limit (about 10 ng) and the possibility of concentrating AZT quantitatively in as much as 5 mL of plasma or serum, the method can be used in routine monitoring of AZT as well as in pharmacokinetic studies. Nevertheless, before establishing therapeutic drug monitoring for AZT, it still must be determined at what time after the last AZT dose blood specimens should be drawn for correct therapeutic interpretation of the concentration of AZT measured in blood.
已开发出一种简单的等度高效液相色谱法，用于测定患者血清和血浆中的叠氮胸苷（AZT）。用于样品制备的新颖、特异的两步固相萃取方法，从血浆基质中回收AZT的回收率接近定量（95.3%），且仅需对传染性临床样品进行极少的处理。通过AASP系统，通过切换一个保留萃取分析物的小柱盒，实现自动“在线”进样，使其进入高效液相色谱流中。整个高效液相色谱程序显示出令人满意的重现性，标准偏差低（变异系数：2.1%）。由于检测限低（约10 ng），且有可能在多达5 mL的血浆或血清中对AZT进行定量浓缩，该方法可用于AZT的常规监测以及药代动力学研究。然而，在建立AZT的治疗药物监测之前，仍必须确定在最后一次服用AZT剂量后何时采集血样，以便对血液中测得的AZT浓度进行正确的治疗解读。
